Latest Us Expansion News

Page 6 of 25
Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.
Ada Torres
Ada Torres
24 Feb 2026
Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.
Ada Torres
Ada Torres
24 Feb 2026
Perenti Limited reported steady half-year revenue of $1.73 billion with a 10.9% increase in net profit, underpinned by a $300 million Dalgaranga contract and growing drilling services in the US. The company also announced an unfranked interim dividend and a CEO transition underway.
Maxwell Dee
Maxwell Dee
23 Feb 2026
Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.
Victor Sage
Victor Sage
20 Feb 2026
Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.
Ada Torres
Ada Torres
20 Feb 2026
Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.
Victor Sage
Victor Sage
20 Feb 2026
Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.
Ada Torres
Ada Torres
19 Feb 2026
Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.
Ada Torres
Ada Torres
18 Feb 2026
Adherium Limited launches a A$7.52 million equity raising to fund commercial expansion of its Hailie SmartInhaler remote patient monitoring platform targeting asthma and COPD patients in the US. The company aims to scale patient numbers and progress towards value-based care contracts with major insurers.
Ada Torres
Ada Torres
16 Feb 2026
American Tungsten & Antimony Ltd (ASX, AT4) has produced its first antimony ingots from its Utah project, validating its processing approach and advancing its US growth ambitions including a planned Nasdaq listing.
Maxwell Dee
Maxwell Dee
5 Feb 2026
Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.
Ada Torres
Ada Torres
4 Feb 2026
Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.
Maxwell Dee
Maxwell Dee
3 Feb 2026